Wednesday, 1 October 2025
MDT 08:00 / EDT 10:00 / UTC 14:00 / Paris (CEST) 16:00
Istanbul 17:00 / New Delhi 19:30 / Bangkok 21:00 / Beijing 22:00
Registration to this event is very simple and free of charge. Simply log into your IPPA account and click register. If you do not have an IPPA account it only takes a couple of minutes to create an account.
Dr. L. Masae Kawamura will discuss why screening for tuberculosis (TB) infection is essential for global TB control and how Interferon-Gamma Release Assay (IGRA) results should be accurately interpreted. IGRA has become a valuable tool for diagnosing latent TB infection (LTBI), offering key advantages over traditional methods. In this session, Dr. Kawamura will provide a clear framework for interpreting IGRA results, highlight important clinical considerations, and share practical insights and providing practical insights for healthcare professionals.
L. Masae Kawamura, MD has been a tuberculosis (TB) clinician, researcher, advocate, and international educator for more than 30 years. She served as San Francisco’s TB Controller, and Co-Principal Investigator of the Curry International TB Center, a CDC funded Center of Excellence from 1996 to the end of 2011. As a US TB Controller, she was appointed to the Federal Advisory Council for the Elimination of TB (ACET) for eight years, the last three as chair and was a member of numerous policy workgroups at both the federal and state level. From 2012 to the end of 2020, she worked at QIAGEN as their Senior Director of Scientific and Medical Affairs for TB immunodiagnostics and was on the global development team for new TB diagnostics and immunoassays. Currently, she remains an expert consultant on TB for QIAGEN, serves on the Board of Vital Strategies as a public health expert, and has recently joined American Gene Technologies as a consultant for their novel HIV gene therapy.
